Research at Beyond Air showed that with an increase in concentration of nitric oxide (NO), the killing effect on bacteria improved. This led to the question of “how high must the concentration be to kill cancer cells”? Well, the answer is >10,000 parts per million which is extremely toxic to humans. This brought us to wonder if the NO gas could be controlled and target only the cancer cells. Once control of the NO gas was demonstrated, Beyond Cancer was born. We call our therapy UNO (Ultra-high Nitric Oxide).
Through subsequent research and development, we have proven in rodent models that gaseous UNO may prevent metastatic disease and has shown a doubling of the survival rate when used in combination with anti-PD1 therapy versus anti-PD1 therapy alone. In addition, safety and an immune response has been demonstrated in humans as a monotherapy. Our next hurdle is human studies in combination with anti-PD1 therapy where we will further optimize dosing and the delivery system while furthering our goal of potentially reducing the death rate for solid tumors.
We believe that we have only scratched the surface of what UNO can provide to cancer patients and their families around the world.
Since 2017, Steve has served as CEO and Chairman of the Board of Beyond Air (XAIR). He brings to Beyond Cancer 18 years of experience as a healthcare investor and 9 years as a healthcare executive with positions of Chief Executive Officer and SVP, Head of Strategy and Business Development.
Selena brings to Beyond Cancer her experience of 16 years as Head of Healthcare Investments at Bailard managing the Emerging Life Science strategy and more than 25 years as a healthcare investor overall. She earned her MBA and MD from Stanford University.
Bob has been a board member at Beyond Air (XAIR) since February of 2019. His 30+ years of healthcare industry experience include positions such as Cofounder, President, and Chief Operations Officer of ACELYRIN; Executive Vice President and Chief Business Officer at Horizon; and Managing Director and Head of Healthcare Investment Banking at JMP Securities.
David brings over 30 years of healthcare executive experience leading global medical device companies. He served at Zimmer Biomet Holdings as President and CEO and led the acquisition and integration of Biomet in 2014. His prior experience includes executive officer with STERIS Corporation, the Board of Directors of St. Jude Medical, Inc., the Advanced Medical Technology Association, and the Orthopaedic Research and Education Foundation.
Greg is an independent oncologist focused drug development consultant. He has 30+ years of experience and has served as President of R&D and CMO of GT Biopharma, CMO of Celularity, executive roles at Verastem, Sideris Pharmaceuticals, BIND Therapeutics, Abraxis BioScience, Intellikine, and served on the integration leadership team during the Celgene acquisition of Abraxis in 2010.